The expanding prevalence of numerous diseases and disorders such as neurological disorders, autoimmune disorders, neurological disorders, bleeding disorders, and others will bring extensive growth opportunities for the plasma protein therapeutics market during the forecast period of 2019-2027. In addition, this therapy is also used for treating a range of rare diseases. These factors will help the plasma protein therapeutics market to gain considerable growth during the forecast period.
Plasma protein therapy is a biologic medicine treatment type used in curing a plethora of diseases and disorders. These therapies are generally given through injections and infusions. Precisely the production of such therapies begins with plasma, a biologic starting material. The growing popularity of plasma therapies among a substantial chunk of the populace due to their curing capabilities will bring tremendous growth opportunities for the global market. The utilization of the therapy in treating secondary immunodeficiency, hemophilia, idiopathic thrombocytopenic, primary immunodeficiency, and others will invite immense growth prospects.
Research and development activities form a crucial part of the overall plasma protein therapeutics market growth trajectory. The players in the plasma protein therapeutics market invest greatly in these activities for deriving insights that result in new formulations and discoveries. These discoveries help in generating considerable revenues, eventually influencing the growth rate of the plasma protein therapeutics market.
Further, strategic collaborations also have an important part in the growth cycle of the plasma protein therapeutics market. The merging of Shire PLC with Baxalta, Inc is a classic instance of collaboration initiatives. The players are also in the process of launching new products that help in boosting sales. For instance, Shire PLC had launched Vynase, the only FDA-approved drug for treating Adult Binge eating disorder. Such developments bode well for the growth of the plasma protein therapeutics market.
Transparency Market Research’s (TMR’s) report on the plasma protein therapeutics market has every component that will assist the stakeholder in understanding the current scenario. The overall market research survey on plasma protein therapeutics by TMR suggests a stable growth period.
According to the TMR experts, the market for plasma protein therapeutics is prognosticated to expand at 7 percent CAGR during the forecast period of 2019-2027. In the context of valuation, the plasma protein therapeutics market is estimated to reach a valuation of US$ 35,350.1 mn by 2027 and was valued at US$ 22,413.9 mn in 2018.
Expansion of Immunoglobulin Usage to Paint Strokes of Growth across Plasma Protein Therapeutics Market
Over the years, plasma-derived immunoglobulin (IG) has emerged as a feasible treatment option not only for primary immunodeficiency, but also for other conditions such as acute inflammatory conditions and autoimmune disorders. This aspect has increased the popularity of plasma-derived IG substantially.
Intravenous immunoglobulin (IVIG), a sub-type of immunoglobulin, is expected to bring exponential growth for the plasma protein therapeutics market. IVIG contains antibodies that protect against numerous viral and bacterial infections. Thus, these factors assure thriving growth for the plasma protein therapeutics market. The immunoglobulin segment is estimated to bring tremendous growth prospects for the plasma protein therapeutics market during the forecast period,
North America to Emerge as Champion Growth Contributor for Plasma Protein Therapeutics Market
The demand for IVIG is increasing at a phenomenal rate in North America. This aspect will profoundly impact the growth of the plasma protein therapeutics market in North America. Further, the C1 esterase inhibitors segment is also stated to observe high CAGR. These factors will assure exponential growth for the plasma protein therapeutics market in North America.
Some well-entrenched players in the plasma protein therapeutics market are Octapharma USA, Inc., CSL Behring, China Biologics, GRIFOLS, S.A, and Biotests.
The Plasma Protein Therapeutics Market has been segmented as follows:
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of analysts, researchers, and consultants, uses proprietary data sources and various tools and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453